Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist, known for his expertise in spectroscopy and materials research, will provide scientific guidance to support the company's research and development efforts.
Uwe Perbandt, CEO of Viromed Medical AG, stated, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH.
With over 180 publications and approximately 4,000 citations, Prof. Rubhausen has contributed to renowned scientific journals, including Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Another focus of his work is the methodological development of AI-supported analysis workflows for complex and high-dimensional datasets.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products. The company, listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. Viromed serves a broad customer base in the DACH region and beyond, aiming to advance the use of cold plasma technology in medicine and realize its growth potential.
This appointment underscores Viromed's commitment to integrating cutting-edge scientific expertise into its product development. By leveraging Prof. Rubhausen's knowledge in spectroscopy and materials research, the company aims to deepen its understanding of cold plasma interactions with biological tissues, potentially leading to more effective medical treatments. The strategic move is likely to bolster Viromed's research capabilities, positioning it to maintain a competitive edge in the rapidly evolving field of cold plasma medicine.
